Guided Tissue Regeneration Indications

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2009-11-20
EMA Refused: Gemesis (becaplermin) — BioMimetic Therapeutics Ltd
EMA refused Gemesis (becaplermin) by BioMimetic Therapeutics Ltd for guided tissue regeneration and periodontal use.